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What Passes Through a Baby 's Skin? 
Babies born at term have a well-developed epidenTlis that is sev-
eral layers thick and that acts as an excellent barrier. But those 
born at 30 weeks gestation have an immature epidermis consisting 
of just two or three cell layers, a poorly defined stratum corneum, 
and little keratinization. They also have a much more permeable 
epidermis. In this issue, Nicholas Barker, Jonathan Hadgraft, and 
Nicholas Rutter of City Hospital in Nottingham, England , quan-
tify permeablity di fferences in the skin of babies and suggest 
clinical implications of their finding. 
The resea rchers studied excised skin samples, obtained at au-
topsy, from 14 infants. The infants ranged from 25 to 30 weeks 
gestation to 8 days old . In an in vitro test, they measured the 
~kin 's permeability to sa li cylates and found that the epidermis of 
mfants of 30 weeks gestation is 100 to 1000 times more permeable 
than that of full term infants. 
The conseq uence, says Rutter, is that "anythin g that is applied 
to the skin of a premature in fant is likely to be rapidly abso rbed." 
There are many reports in the litera ture in which substances, 
including an iline dyes, hexachlorophene, methylated spirits, and 
neomycin have been topicall y applied to the skin of premature 
babies and have poisoned them. 
On the other hand , Rutter notes , the high permeability of the 
skin of premature in fants can be turned to their advantage. The 
epidermis, he says, can be "an alternate route fo r dru g absorp-
tion." For example, Rutter and his colleagues find, the drug the-
ophylline, wh ich is used to treat apnea in premature in fants, cur-
rently is adm inistered ora ll y or intraveno Llsly. The ora l route is 
" unreliable," Rutter says, beca use the babies have immature 
di gestive tracts. T he in travenous route is difficult because it can 
be hard to maintain an intravenous line for the 1 to 2 weeks of 
treatment. But, Rutter and his colleagues find , w hen th ey apply 
theophylline to the abdom inal skin of premature infants, the dru g 
is absorbed and reaches therapeutic levels in the blood . 
What Does CSa Really Do? 
Investigators have always ass umed that the small molecu le C5a, 
w hich is a potent med iator of inflammation in the skin, causes a 
wheal and fl are reaction because it degranulates mast cells. But 
that assumption may not be correct, according to Kim Yancey, 
Leonard Bielory, Ralph Wright, Nea l Young, Michael M. Frank , 
and Thomas Lawley of the National Institutes of Health. They 
report their res ults in this iss ue. 
Lawley and his associates showed previously that C5a causes 
a w heal and fl are reaction w hen it is injected into the sk in . More-
over, he reported that if he biopsied the skin after he inj ected 
CSa, he found increased vascular permeability and mast cel l de-
generation. T hey also found polymorphonuclear neutrophils 
(PMNs) infiltrating the blood vessel wall and going into the in-
tersti tial tissue. 
Whether C5a directly affected mast cells (or another cell type 
such as PMNs) to induce the w heal and flare was unknown , but 
appeared to be the most plausible mechanism . Lawley and his 
colleagues decided to investigate the actions of C5a more closely 
by distin guishin g its in vivo effects on mast cells from its well 
known effects as a chemoattractant. H e explains that C5a attracts 
PMNs and monocytes, w hich is the reason that these white blood 
cells come out of nearby blood vessels w hen C5a is inj ected into 
the skin . 
To determine whether C5a has a direct effect on dermal mast 
celJs Lawley and his associates injected C5a into indi viduals w ho 
have no w hite blood cells-patients with bone marrow failure. 
" We expected that the w heal and flare reaction would not be 
much different in these patients even thou gh there ')¥ou ld be no 
w hite blood cells aro Llnd the blood vessels," Lawley says. 
To the group 's surprise, the patients had a diminished w hea l 
and flare reaction to th e injected C5a. "Our first res ponse was to 
try other substances that ca use wheal and flare," Lawley recalls. 
"We injected histamine, and the patients reacted normally." They 
then tri ed injecting morphin e, w hich ca uses mast cell degranu-
lation . Once aga in , the patients had a normal w heal and flare 
reaction. 
"The patients with bone marrow fa ilu re rea cted abnormally 
onl y to C5a," Lawley says. " This sugges ts that part of the im-
mediate wheal and flare reaction must be mediated by PMNs and 
probably by a substance they release." This finding corrobora tes 
observations in anima ls given ant ica ncer drugs that decrease th eir 
w hite blood cell count. T he anima ls subsequently have a decreased 
cutaneous response to C5a, Lawley points out. T he PMNs ma y 
release a substance that itself ca uses a w hea l and fl are reaction o r 
they may rel ease a substance that acts on mast cells and causes 
them to degranulate. But whatever the exp lanation turns out to 
be, the group 's results have laid to rest the conventional wisdom 
of how C5a ca uses the w hea l and flare reaction by degranulatin g 
mast cells. 
Understanding Wound Healing 
When skin is wounded , keratinocytes migrate over the wound 
and interact with the underlyin g tissue. But how do they interact? 
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What chemica l components are involved, and is there a difference 
between the attachment of keratinocytes to the wound and their 
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spread in g over it ? Two papers in this issue are concerned with 
differen t biochemical aspects of wound healing . The res ults, taken 
together, provide new insights into how the process occurs. 
Ken-ichj Toda and Frederick Grinnell of the University of T exas 
H ealth Science Center in Dallas fo und prev io usly th at receptors 
fo r th e adhes ion m olecule fibronectin appea r on keratin ocytes 
durin g wound hea ling . C ultured kera tin ocytes, whi ch act like 
keratinocytes fro m a w o und , have fi bronectin receptors wh ereas 
freshl y iso lated keratin ocytes do no t. And keratin ocytes norm all y 
co me in contac t w ith fib ronectin onl y w hen they are healing a 
wound . T he impli cation is that fibronectin pl ays a unique role 
by allowin g keratin ocytes to attach to the wound . 
In his current J 10 paper, Grinnell says , "we attempt to take 
the nex t step. " H e and T oda asked w hether fibronectin is a unique 
attachment mo lecule. If you coa t substrates w ith o ther substances 
that m ay prov ide adhesion , including coll agen , basem en t m em-
brane, concanavalin A, and w hea t germ agglu tinin , will cultured 
keratinocytes bind as well as th ey do to a fibron ectin-coa ted sub-
strate? And does it m ake any difference if fibronectin is there 
w hen the keratinocytes start to spread? 
Grinnell and T oda com e to two co nclusions. The first is th at 
" Wh en it com es to attachment to the m atrix , only fibron ectin is 
regul ated ." C ultured keratinocytes were more than 30 times as 
active in their attachment to fibron ectin-coa ted substrata than 
were freshl y isolated keratin ocytes. But the cultu red and freshl y 
isolated keratinocytes we re equall y acti ve in attachin g to the o ther 
substrata coa tin gs th at Grinnell and T oda tes ted . 
The second conclusion is that fibronectin is no m ore effective 
than other substances tes ted in stimulatin g th e keratinocytes to 
spread . N o m atter w hat coated substratum the cells were on, they 
began ac tively spreading around on day four o f the experim ent. 
Shinji M o rioka, Gerald Lazurus, J anet B aird , and Pa melaJensen 
of the Uni versity of Pennsylvania School of Medicine asked whether 
keratinocytes th at are migratin g into a w ound use plasminogen 
activator and, if so, ho w. Plasminogen activator is a protein-
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degrading enzym e that seems to enhance proliferation o r migra-
tion in a variety of cell types, including m acrophages, Sch wanl1 
cells, develo ping neurons and gli al cell s, and hem o poietic cells 
colonizin g the develo ping bursa o f Fabriciu s. Several in ves tigators 
repo rt tha t the protein is linked to termin al differentiatio n in 
keratinocy tes . 
In this issue, Laza ru s and his colleagues provide evidence that 
plasmin ogen activator m ay be impo rtant for th e movem ent of 
keratin ocytes that begins within hours o f wounding . 
Laza rus and his associates began by w oundin g cultured human 
keratinocy tes by cuttin g through them. Then they u'sed antibodies 
aga inst plas minogen activator to po int to the presence of this 
pro tein . The cells al ong the leadin g edge o f the w ound , Laza rus 
fi nds, contain plas minogen activator. M oreover, what these cells 
must do is mi grate, no t necessa ril y di vide, he reports, because 
w hen he prevents cell division, they still m ove to fill in the woun d. 
So plas minogen acti va to r might have so mething to do w ith mi-
g ration . 
Yet there is no obvious reason w hy keratin ocytes in this celJ 
culture system w ould need a protein-degradin g enzym e to m ove. 
Laza rus proposes th at in vivo , the keratinocytes need the enzym e 
beca use they mig rate on a fibrin m atri x and they have to cut their 
w ay thro ug h. There is som e evidence that this partially dissolved 
fibrin m o re effi ciently pro m otes the mi gration of the keratino-
cytes. Finally, Laza rus proposes, plas minogen activa tor m ost likely 
dissolves that fibrin m atrix when the wound is healed . 
So, on the basis o f two papers, it now appears that w o und 
healing starts w hen fibron ectin pro m otes the adhesion o f kerat-
inocytes to th e wounded surface. Fibronectin also promotes the 
g ro wth o f the keratin ocy tes, and w hil e the cell s are migrating 
over the wound , th ey release plasmin ogen activator , which en-
ables them to cut throu gh the fibrin m atrix and possibl y be more 
responsive to fibron ectin in the first pl ace. In addition , it appea rs 
th at the mig ration o f keratinocytes may be regulated separately 
from th eir growth . 
